The discovery and development of TB drugs has met limited success, with two new drugs approved over the last 40 years. Part of the difficulty resides in the lack of well-established in vitro or in vivo targets of potency and physicochemical and pharmacokinetic parameters. In an attempt to benchmark and compare such properties for anti-TB agents, we have experimentally determined and compiled these parameters for 36 anti-TB compounds, using standardized and centralized assays, thus ensuring direct comparability across drugs and drug classes.
Introduction
One-third of the world's population is infected with TB, of whom 5%-10% may develop active TB in their lifetime. 1 Mycobacterium tuberculosis (Mtb) is the causative agent of TB, a disease that causes 1.4 million deaths each year. In 2012, around 8.6 million people developed TB (including 400 000 MDR TB cases). 2 The treatment of TB is becoming challenging due to the emergence of MDR TB and XDR TB, and increasing numbers of TB-HIV coinfections. Recent reports of totally drug-resistant 3 TB cases that are resistant to all anti-TB drugs further emphasize the need for novel drugs that are active against all forms of TB.
It is widely recognized that, apart from in vitro potency on target, physicochemical and pharmacokinetic (PK) properties need to be considered early in drug discovery. Following studies in the late 1990s indicating that poor PK and toxicity were important causes of costly late-stage failures in drug development, in vitro assays of absorption, distribution, metabolism and elimination (ADME), as well as in vitro toxicity assays, were integrated into the early stages of drug discovery. Early in vitro ADME and toxicity assessment resulted in a dramatic reduction of attrition associated with poor drug exposure and adverse events. 4 Physicochemical parameters affect absorption, oral bioavailability and other ADME parameters. Experimental and computational analyses of very large sets of small-molecule drugs resulted in Lipinski's rule of five, whereby poor absorption or permeation is more likely if a compound exhibits one or more of the following properties: molecular weight (MW) .500, calculated logP or octanol:water partition coefficient (cLogP) .5, hydrogen bond donors (HBD) .5 or hydrogen bond acceptors (HBA) .10. 5 Veber's rule added that compounds with ,10 rotatable bonds and a polar surface area (PSA) ,140 Å 2 are more likely to have good oral bioavailability. 6 Further, Gleeson's analysis revealed that almost all ADME parameters deteriorate with increasing MW, logP or both, thus recommending MW ,400 and cLogP ,4 to improve ADME parameters. 7 In addition, Egan et al. showed that cLogP and PSA could be used as a tool (the Egan Egg model) for predicting good passive gut absorption. 8 In early drug discovery, emphasis is most often placed on in vitro potency, while desirable physicochemical and PK parameters are considered as secondary attributes in the decision-making process. To be efficacious, anti-infectives have to (i) effectively penetrate the microbe and inhibit an essential cellular process and (ii) reach the site of infection-lung tissue and lesions for pulmonary TB. Hence, the chemical space occupied by antibacterials 9 and antimycobacterials 10 is distinct from that of drugs targeting non-infectious diseases.
Recently, Franzblau et al. 11 carried out a comprehensive analysis of various microbiological and animal study protocols used by different TB research groups to characterize compounds. A guide for medicinal chemists to optimize compounds against TB has also been discussed. 12, 13 Further, the physicochemical, biopharmaceutical and clinical PK -pharmacodynamic (PD) properties of selected anti-TB compounds and novel agents under development have been reviewed.
14 -20 These reviews do not include comparative analyses and correlation between in silico, in vitro and in vivo properties. Here we have generated in vitro potency and in vitro PK for a set of 36 compounds using standardized procedures. In silico physicochemical and in vivo pharmacological parameters have also been compiled. We have used computational approaches to seek relationships between in silico, in vitro and human in vivo parameters to guide early drug discovery efforts against TB. Not surprisingly, lipophilicity emerged as a major factor driving the in vitro and in vivo PK properties.
Materials and methods

Bacterial strains, culture media and chemicals
Mtb H37Rv (ATCC #27294) was maintained in Middlebrook 7H9 broth supplemented with 0.05% Tween 80 and 10% ADS (5% albumin, 2% dextrose and 0.81% sodium chloride) supplement. Alternatively, Dubos broth (Difco) supplemented with 0.05% (v/v) Tween 80, and 10% Dubos medium albumin (Difco) was used for the Wayne hypoxia model. 21, 22 For nutrient starvation (the Loebel model), Mtb cells grown in 7H9 medium were washed and resuspended using PBS supplemented with 0.25% Tween 80 and rolled in a 1 L roller bottle for 14 days at 378C as described elsewhere. 23 All the standard compounds were obtained from commercial sources except for bedaquiline (TMC-207), PA-824, delamanid (OPC-67683) and PNU-100480, which were synthesized at Novartis. Stock solutions of the compounds were prepared using 90% DMSO. The 36 compounds used in the study (Table 1) were isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, kanamycin, amikacin, p-aminosalicylic acid, cycloserine, ethionamide, rifabutin, rifapentine, moxifloxacin, levofloxacin, gatifloxacin, ciprofloxacin, ofloxacin, sparfloxacin, capreomycin, thioacetazone, linezolid, prothionamide, clarithromycin, amoxicillin, clavulanate, meropenem, clofazimine, metronidazole, thioridazine, mefloquine, vancomycin, valnemulin, PNU-100480, PA-824, bedaquiline and delamanid.
Physicochemical parameters
Data on MW, cLogP, PSA (which measures the surface sum of the overall polar atoms), rotatable bonds, HBD and HBA were generated using proprietary software based on standard algorithms (Medchem FOCUS).
MIC 50 determination
MIC 50 was determined using the laboratory strain Mtb H37Rv by turbidimetric assay as previously described, 24, 25 with slight modifications. Briefly, compounds dissolved in 90% DMSO were 2-fold serially diluted in duplicates and spotted by mosquito HTS liquid handler (TTP LabTech, Hertfordshire, UK) in to 384-well clear plates, resulting in 10 dilutions of each compound. A volume of 50 mL of Mtb culture (final OD 600 of 0.02) was added to each well, and the plates were incubated at 378C for 5 days. OD 600 values were recorded using a SpectraMax M2 spectrophotometer and MIC 50 curves were plotted using Graph Pad Prism 5 software. Compounds dissolved in 90% DMSO were 2-fold serially diluted in duplicates and spotted by mosquito HTS liquid handler (TPP LabTech) in to 96-well plates, resulting in 10 dilutions of each compound. Depending on the assay, we added 200 mL of either aerobically growing Mtb or 14-day-old Loebel nutrient-starved non-growing Mtb cells to each well and the plates were incubated at 378C under aerobic conditions for 5 days for the determination of MBC and LCC, respectively. 21, 23, 24 Rifampicin (8.22 mg/L) and isoniazid (13.7 mg/L) were used as positive and negative controls, respectively, during LCC determination. For WCC determination, 200 mL of Mtb H37Rv that had been subjected to growth in the Wayne hypoxia model 21, 22 for 20 days was added to 96-well plates containing serially diluted compounds and the plates were incubated under hypoxic conditions for 5 days at 378C. Metronidazole (68.5 mg/L) and isoniazid (4.3 mg/L) were used as positive and negative controls, respectively, during WCC determination. Viability was determined by plating on 7H11 agar plates and by cfu determination. The concentration at which 90% of the initial inoculum was killed after 5 days of incubation under aerobic, nutrient-rich conditions was defined as the MBC 90 . Similarly, a 90% reduction in the number of viable bacteria under aerobic, nutrient-starved and hypoxic, nutrient-rich conditions was defined as the LCC 90 and WCC 90 , respectively .
Macrophage assay
All compounds were profiled for their activity against Mtb-infected mouse macrophage cells (RAW264.7) at the Institut Pasteur, South Korea, using standard procedures. 26 
Cytotoxicity
Cytotoxicity was tested in HepG2 (ATCC #HB-8065) and BHK-21 (ATCC #CCL-10) cell lines in 96-well microplates as described elsewhere. 25 Relative fluorescence units were measured at OD 450 using a Tecan Safire 2 and CC 50 curves were plotted using Graph Pad Prism 5 software.
In vitro PK studies
In vitro PK parameters such as solubility, permeability [parallel artificial membrane permeability assay (PAMPA) and Caco-2] and metabolic stability Lakshminarayana et al.
in mouse and human liver microsomes were measured at Cyprotex using standard protocols as described at www.cyprotex.com/admepk/. 27, 28 Thirty-two compounds were profiled in various assays. Thermodynamic solubility was determined in PBS buffer at pH 7.4 using HPLC-UV. For solubility (mg/mL), the mean values from two independent replicates are given. Mean apparent permeability (P app with units being 10 26 cm/s) values from four replicates are given for PAMPA permeability. Caco-2 permeability was provided as mean P app (10 26 cm/s) (i) from apical to basolateral (A-B) and (ii) from basolateral to apical (B-A), as well as the ratio between the two values, from two independent replicates. In vitro metabolic stability in both mouse and human liver microsomes was determined and their intrinsic clearance (mL/min/mg protein) values are given. PAMPA, Caco-2 and metabolic stability sample analysis was carried out using optimized LC-MS/MS methods.
Mouse in vivo PK and efficacy studies
All procedures involving mice were reviewed and approved by the institutional animal care and use committee of the Novartis Institute for Tropical Diseases. Animal studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals. All animals were kept under specific pathogen-free conditions and fed water and chow ad libitum, and all efforts were made to minimize suffering or discomfort.
In vivo PK data for ethambutol, cycloserine, ethionamide, mefloquine, clofazimine, valnemulin and PA-824 were obtained in CD-1 female mice. For isoniazid, rifampicin, pyrazinamide, moxifloxacin, linezolid and bedaquiline, PK parameters were compiled from the literature (Table S1 , available as Supplementary data at JAC Online). The compounds were formulated either in 0.5% carboxy methyl cellulose or 10% hydroxypropyl-b-D-cyclodextrin suspension and 10% lecithin in water for PA-824 29 and administered orally 30 Groups of three mice were used for each timepoint. Blood was centrifuged at 13 000 rpm for 7 min at 48C and plasma was harvested and stored at -208C until analysis. Plasma samples were analysed using optimized LC-MS/MS conditions and PK parameters were calculated using WinNonlin software version 5.1.
In vivo acute mouse efficacy studies were carried out as described earlier. 11, 25 Briefly, animals were infected intranasally with 10 3 Mtb H37Rv bacilli. One week post-infection, animals were treated for 1 month with the appropriate dose. At 2 and 4 weeks post-dosing, the lungs were aseptically removed and homogenized and the bacterial loads were estimated by plating serial dilutions on 7H11 agar plates. Mean log cfu reductions (mean+SD) were calculated from five animals at each timepoint and compared with untreated controls.
Statistical analysis
Correlations were tested using TIBCO Spotfire version 4.0.2 (http://spotfire. tibco.com). Statistical analysis was carried out using Prism software (GraphPad Prism, version 5.02, San Diego, CA, USA; www.graphpad.com). A Spearman's correlation analysis was performed to determine the relationship between various parameters.
Results and discussion
To benchmark and compare the physicochemical, potency and PK properties of the available anti-TB agents, we experimentally determined and compiled these parameters for 36 anti-TB compounds using standardized and centralized assays, thus ensuring direct comparability across drugs and drug classes. The compound set included first-and second-line anti-TB agents, clinical candidates as well as drugs that exhibited in vitro activity against Mtb (Table 1) . Of the 36 compounds selected, 15 were natural products (compounds of natural origin and semi-synthetic derivatives) and the remaining 21 were fully synthetic molecules. The majority of these drugs are administered orally, with a few injectables. Half of the compounds were initially developed as either Gram-positive or Gram-negative antibacterials. These were introduced as part of combination regimens for the treatment of MDR TB due to the emergence of resistance to first-line anti-TB drugs (Table 1 and Figure S1 ).
Physicochemical properties
Physicochemical parameters and Lipinski rule violations are presented in Table 2 . Most compounds follow Lipinski's rule of five and Veber's rule with MW ,500 (n¼25), cLogP ,5 (n¼30), HBD ,5 (n ¼ 29) and HBA ,10 (n ¼ 27), and with PSA ,120 Å 2 (n ¼ 26) and rotatable bonds ,10 (n¼ 34), which is predictive of good oral bioavailability (Table 2) . 5, 6 The majority of the compounds display acceptable drug-like properties with cLogP ,5, the exception being natural product derivatives such as aminoglycosides and rifamycins (Figure 1a -e) . All compounds were subjected to the Egan Egg analysis (Figure 2) . 8 Twenty-four compounds were within the inner ellipsoid and are therefore predicted to exhibit good passive absorption through the gastrointestinal tract, in agreement with acceptable oral bioavailability (Table S2) . Compounds falling outside the ellipsoid are natural products (Table 1) . Interestingly, both rifampicin and rifapentine have good oral bioavailability in humans, suggesting that they may be actively transported. 8 Amoxicillin, located on the borderline of the ellipsoid, is known to be absorbed by active transport processes. 31 
Biological profiling of anti-TB compounds
Mtb in human lung lesions exists in growing and non-growing states. Further, bacilli can be found extracellularly and intracellularly. Therefore, a battery of in vitro potency assays is employed to characterize the antimycobacterial properties of substances under various conditions, in addition to standard determinations of growth inhibition and cidal activity. While these data are for the most part available in the literature, we sought to generate a centralized dataset using standardized assays in a single laboratory, thus eliminating interlaboratory variability and generating values that can be reliably compared across compound classes. The results are presented in Table 3 . Compounds displayed a wide range of MIC 50 values, from 0.01 to 11 mg/L (Table 3) . Pyrazinamide, metronidazole, meropenem and amoxicillin were found to be inactive (MIC 50 .30 mg/L). Pyrazinamide, known to be inactive in standard neutral pH medium and to require an acidic pH to exert its growth inhibitory activity, showed an MIC 50 of 25 mg/L at pH 5.5. Although metronidazole was inactive against growing Mtb, it was active against hypoxic non-growing Mtb with a WCC 90 of 8.56 mg/L (Table 3) . 22 Meropenem in combination with clavulanate has shown good inhibitory activity both in vitro and in vivo 32, 33 but when tested individually neither drug showed any in vitro inhibitory activity against growing or non-growing Mtb (Table 3 ). The MIC 50 data presented in the current study are comparable to the data obtained by Franzblau et al.
11 using similar media. Two-thirds of the compounds tested showed cidal activity against replicating Mtb. For cidal compounds, the MBC 90 values were in general 2-to 4-fold greater than the MIC 50 values. Some compounds, such as p-aminosalicylic acid, linezolid, thioacetazone, vancomycin and PNU-100480, showed low MIC values but had poor cidal activity. For bedaquiline, only weak cidal activity was observed with the standard incubation time. The discrepancy between this and published data is likely to be due to the longer incubation time required to detect a full cidal activity of bedaquiline. 34 Approximately two-thirds of the compounds were active against intracellular Mtb at a concentration of 5 mg/L or lower (Table 3) .
Two models of non-growing Mtb were employed: the Wayne model (where the dormant state is induced by oxygen starvation) and the Loebel model (where Mtb is subjected to nutrient starvation). In general, non-growing Mtb was not affected by most compounds (i.e. the concentrations that killed 90% of the initial inoculum were greater than the highest concentrations tested, which ranged between 10 and 145 mg/L) ( Table 3) . Rifampicin, rifabutin and rifapentine were the most active compounds against the 'Wayne' and 'Loebel' bacilli. Aminoglycosides, fluoroquinolones, capreomycin, clofazimine, metronidazole, thioridazine and mefloquine showed moderate activity against hypoxic non-growing Mtb cells. Bedaquiline showed good WCC 90 activity, followed by PA-824. Most of the WCC 90 and LCC 90 data obtained in the present study are comparable to published results. A cytotoxicity (CC 50 ) measurement was carried out using two common cell lines, namely BHK-21 (kidney cell line) and HepG2 (liver cell line). Most compounds tested were non-cytotoxic up to a maximum concentration tested (2.5 -29 mg/L), with CC 50 to MIC 50 ratios of Lakshminarayana et al. (Table 3) . It is important to note here that many anti-TB agents are pro-drugs that are primarily activated inside Mtb. Cytotoxicity assays in human cell lines do not capture the potential toxicity of these active metabolites if bioconversion does not take place within host cells.
In vitro PK
In vitro solubility, permeability and liver microsomal metabolic stability are key predictors of oral bioavailability. These properties were determined using standardized assays and are summarized in Table 4 . Ninety percent of the compounds showed moderateto-high solubility, except clofazimine, PA-824 and bedaquiline, which were poorly soluble. For predicting permeability, PAMPA is employed as a simple in vitro model of passive diffusion through an artificial membrane. The Caco-2 cell layer permeability assay is widely used as a more predictive in vitro model of absorption through the intestinal epithelium. While PAMPA only measures passive diffusion, the Caco-2 assay integrates active uptake, efflux and permeation via the paracellular route. Most of the compounds (62%) exhibited low PAMPA permeability while 90% of the compounds showed moderate to high Caco-2 permeability and no or low active efflux except for rifampicin, thioacetazone and clarithromycin. Exceptions were streptomycin and clofazimine displaying low Caco-2 permeability. More than 90% of the compounds displayed low-to-medium intrinsic clearance in both mouse and human liver microsomes. There was a good correlation between the two species, except for ethionamide and prothionamide, with high and medium clearance in mouse and human microsomes, respectively (Table 4) .
Correlations between in silico, in vitro and in vivo parameters
As expected, some level of correlation was observed between in vitro PK and physicochemical properties. Generally, compounds with MWs ,400 and cLogP of ,4 showed better solubility and Caco-2 permeability (Figure 3a -d) . This is in agreement with Gleeson's findings. Most of the outliers were natural products either belonging to the rifamycin class or aminoglycoside injectables. There was a significant negative correlation between solubility and cLogP (r s ¼ 20.5824, P ¼ 0.0007) (Figure 3b) . Further, examination of clinical PK parameters retrieved from the literature (Table 1) . Lakshminarayana et al. (Table S2 ) revealed a moderate-to-high oral bioavailability for compounds that follow Lipinski's rule of five and Veber's rule ( Figure S2A -E) , 5, 6 as well as compounds with a solubility of .1 mg/mL and Caco-2 of .5×10 26 cm/s ( Figure S2F and G) . In addition, a significant positive correlation was observed between (i) cLogP and volume of distribution, an indicator of drug distribution into tissues (Figure 4a ), (ii) cLogP and systemic clearance of the unbound fraction ( Figure 4b ) and (iii) cLogP and plasma protein binding (Figure 4c) . A significant negative correlation was observed for cLogP and oral bioavailability (Figure 4d ). As expected, lipophilicity emerged as an important parameter influencing in vitro and in vivo PK parameters. Mtb possesses a notoriously impermeable cell wall. Thus, we tested the hypothesis that lipophilicity and permeability could be a determinant of in vitro potency. Across all drug classes included in this study, no significant correlation was observed between antimycobacterial activity and cLogP, PAMPA or Caco-2 permeability, indicating that permeability and/or lipophilicity is not a predictor of activity inside the mycobacterium, at least not across this large set of compound classes. Examination of potential correlations within subgroups of compounds (natural products, synthetic molecules, injectables and oral drugs) did not reveal any apparent association either. Within a given series, however, a positive correlation is often detected between cLogP and potency, as recently published for indolcarboxamide and tetrahydropyrazolopyrimidine carboxamide series. 35, 36 (Table 1) . r s is the Spearman's rank correlation coefficient and P is the level of significance.
In vitro and in vivo profiling of antimycobacterials
Correlations between in vivo PK and in vivo efficacy
To examine the PK -PD relationships of anti-TB compounds, mouse in vivo PK and efficacy data were either retrieved from the literature or generated as part of this study (Table S1 ). Doses were selected based on the efficacious exposure observed in humans. Based on the MIC 50 and PK parameters, plasma PK -PD indices (fC max /MIC, fAUC/MIC and fT .MIC ) were calculated and corrected for plasma protein binding to reflect the free drug fraction (indicated by 'f') ( Table 4) . Overall, unbound C max values were above the MIC at some point during the dosing interval, except for compounds with high plasma protein binding such as mefloquine, clofazimine and bedaquiline (Table 4 and Table S1 ). Except for PA-824-for which efficacy is driven by the fraction of the dosing interval during which free plasma concentration exceeds the MIC or fT .MIC -the efficacy of all the compounds tested was concentration dependent, i.e. either fAUC/MIC and/or C max /MIC best correlated cfu reduction in mouse lungs. 37 -41 However, no clear trend was observed between PK -PD indices and mean log cfu reduction across compounds or compound classes. This is an important observation and clearly shows that simple PK -PD rules of thumb cannot be used to guide the discovery and development of novel TB drugs. 13 This feature is specific to TB drugs and is in stark contrast to many other antibacterials for which plasma PK -PD indices usually fall within relatively narrow and reasonably predictive windows. 42 The complexity of the pathology of TB, where the pathogen resides in remote lesion compartments, is likely to contribute to the lack of correlation between plasma PK and efficacy. 43 
Conclusions
Drug discovery aims to deliver a candidate that shows efficacy, exposure and tolerability in a relevant animal model and in man. In silico and in vitro assays are employed in lead finding and optimization, attempting to predict these in vivo properties. In the present study, we have comprehensively determined and compiled physicochemical parameters, in vitro PK properties and potency values for 36 antimycobacterials, most of which are in clinical use against TB. Attempts to detect in vitro -in vivo correlations between physicochemical, PK and efficacy parameters met with limited success, once again highlighting the challenges of anti-TB drug discovery. We hope that this standardized dataset represents a useful reference for the TB drug discovery community.
